1 INTRODUCTION {#SEC1}
==============

A detailed understanding of biological systems requires the ability to trace cause and effect across multiple levels of biological organization, from molecular-level reactions to cellular, tissue- and organ-level effects to organism-level outcomes ([@B16]). Consequently, any effort aiming to comprehensively represent biological systems must address entities and processes at all of these levels.

This challenge has so far been only partially met in biomedical information extraction (IE) and text mining, which aim to improve access to domain knowledge by automating aspects of processing the literature. Until recently, efforts in domain IE were primarily focused on the basic task of recognizing mentions of relevant entities such as genes and proteins in text ([@B43]) and on the extraction of pairwise relations between these representing, for example, protein--protein interactions ([@B17]; [@B24]). Such representations lack the capacity to capture any but the simplest of associations.

In recent years, there has been increasing interest in the extraction of structured representations capable of capturing associations of arbitrary numbers of participants in specific roles. Such approaches to IE, frequently termed *event extraction*, are capable of representing complex associations---such as the binding of a protein to another inhibiting its localization to a specific cellular compartment ([Fig. 1](#F1){ref-type="fig"})---and open many new opportunities for domain text mining applications ranging from semantic search to database and pathway curation support ([@B1]). There is significant momentum behind the move to richer representations for IE: more than 30 groups have introduced methods for biomedical event extraction in shared tasks ([@B14], [@B15]); event-annotated corpora have been introduced for many extraction targets, including DNA methylation ([@B25]), protein modifications ([@B28]) and the molecular mechanisms of infectious diseases ([@B31]); event extraction methods have been applied to automatically analyze all 20 million PubMed abstracts ([@B4]); and event extraction analyses are being integrated into literature search systems such as MEDIE[^1^](#FN1){ref-type="fn"} and applied in support of advanced tasks such as pathway curation ([@B26]). Fig. 1.Example sentence with event annotation. P[rot]{.smallcaps}, -R[eg]{.smallcaps} and C[ell comp]{.smallcaps}. abbreviated for P[rotein]{.smallcaps}, N[egative regulation]{.smallcaps} and C[ell component]{.smallcaps}, respectively

While the event extraction approach has been demonstrated to be applicable to a variety of extraction targets across different subdomains of biomedical science, related efforts all share a key restriction: nearly exclusive focus on molecular-level entities and events.[^2^](#FN2){ref-type="fn"} Entities such as proteins and genes and events such as binding and phosphorylation are an important part of the picture of biological systems, but still only a part, and any IE approach aiming to capture the whole picture must also consider other levels of biological organization.

In this study, our aim is to extend the scope of existing event extraction resources and methods to levels of biological organization ranging from the subcellular to the organism level as a step toward developing the capacity for the automatic extraction of these targets from the entire available literature. Toward this end, we propose relevant entity and event types for annotation across these levels with reference to community-standard ontologies, develop a set of detailed guidelines for their annotation in text and create structured event annotation marking over 8000 entities and 6000 events in abstracts relevant to cancer biology, previously annotated by domain experts to identify spans of text relevant to their interests. Using this data, we perform experiments using state-of-the-art methods for both entity mention detection and event extraction to analyze the feasibility of extraction using existing tools, further evaluating the benefits of specific adaptations of such tools to the novel task.

2 APPROACH {#SEC2}
==========

2.1 Corpus texts and reference annotation {#SEC2.1}
-----------------------------------------

We selected as the starting point for our study a recently introduced corpus of 262 PubMed abstracts on angiogenesis, the development of new blood vessels from existing ones. The domain involves a tissue/organ-level process that is closely associated with cancer and other organism-level pathologies and whose molecular basis is increasingly understood ([@B8]), and domain texts thus represent a good test case for structured IE across multiple levels of biological organization.

The corpus texts were previously annotated by [@B41] using a typed-span representation, marking references to molecular level entities, cells, tissues and domain-relevant processes. We use these annotations created by domain experts as a reference for identifying statements of interest for our annotation, which focuses on introducing structured event annotation and solidifying the ontological basis of the existing entity annotation.

2.2 Representation {#SEC2.2}
------------------

We apply the specific event representation first formalized in the BioNLP 2009 Shared Task on event extraction and applied in numerous resources and methods introduced since. In this representation, Entity mentions (or *entities*, for short) are marked as continuous spans of text identified with a type (e.g. Protein), and event structures (or *events*) are *n*-ary associations of participants---entities or other events---each of which is identified as participating in the event in a specific role (e.g. *Theme* and *Cause*). Each event is assigned a type from a fixed set defined for the task (e.g. Binding and Phosphorylation) and is associated with a specific span of text stating the event, termed the *event trigger*. Events can additionally be marked with *modifiers* identifying the event as being, e.g. explicitly negated, or stated in a speculative context. We refer to ([@B14]) for a detailed presentation of the representation.

Given the starting point of the existing corpus annotations, our event annotation effort proceeds from *spans* to a *structured* representation that can represent complex associations between arbitrary numbers of entities ([Fig. 1](#F1){ref-type="fig"}) and many other aspects that the typed-span representation cannot, such as the direction of causality ([Fig. 2](#F2){ref-type="fig"}). Fig. 2.Span versus structure. Although a representation using nested, typed spans (left) can capture the fact that specific entities participate in a process, it lacks the mechanisms to express, e.g. the direction of causality. The structured event representation (right) differentiates *Themes* from *Causes*

In addition to selecting the general form of representation, to define a specific event annotation scheme, we must also fix the annotated entity and event types as well as the roles, participant scopes and modifiers applied. For these, we build on previously introduced resources targeting the molecular level, basing our extensions on domain ontologies.

2.3 Ontological basis {#SEC2.3}
---------------------

We take as basic the division between continuants (or endurants) and occurrents (perdurants, processes or events) (see e.g. [@B35]) and adopt the general principle followed also in major previously introduced event-annotated resources that references to continuants such as material entities are annotated using the entity representation and references to occurrents such as biological processes are annotated as events.[^3^](#FN3){ref-type="fn"}

In the definition of our annotation scheme, we aim for compatibility with existing event-annotated corpora---primarily the five 'main task' corpora introduced in the BioNLP Shared Tasks---to allow these to be used together with the annotations that we create and to assure that our extensions are coherent with existing resources derived from these corpora. Thus, for molecular-level entity and process types, we adopt the scope, semantics and annotation guidelines of these resources as closely as possible without compromising coverage of mentions marked as relevant by domain experts. For entities and processes not in scope of previous event resources, we propose new types for annotation, basing type and scope definitions and annotation guidelines on major community-curated ontological resources from the open biomedical ontologies (OBO) foundry[^4^](#FN4){ref-type="fn"} ([@B37]). In brief, before primary annotation, we analyzed mentions marked in the reference annotation to identify entity and process types not in scope of previously defined event annotation guidelines and then defined new types and guidelines for annotation with reference to selected ontologies. These are summarized in the following.

2.4 Annotation scheme {#SEC2.4}
---------------------

The focus our extensions of previously proposed event annotation schemes is on *anatomical entities* such as cells, tissues and organs and processes involving them such as growth, remodeling and death.[^5^](#FN5){ref-type="fn"}

For anatomical entity types, we adopt a top-level division by granularity ([@B18]) based primarily on the upper-level structure of the Common Anatomy Reference Ontology (CARO) ([@B11]), an organism-independent ontology of anatomy based on the human-specific Foundational Model of Anatomy ([@B32] , [@B33]), as outlined in our previous work on anatomical entities ([@B30]). To account for pathological anatomy-level entities (e.g. glioma)---out of scope of ontologies of canonical anatomy---we draw on the approach proposed by ([@B36]). [Table 1](#T1){ref-type="table"} summarizes the primary entity types applied in the annotation.[^6^](#FN6){ref-type="fn"}

###### 

Primary entity types, related ontology terms and annotation counts

  Type                                                                       Term(s)                                                                                                  Examples                                              Count
  -------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ----------------------------------------------------- -------
  O[rganism]{.smallcaps}                                                                                                                                                                                                                    
      O[rganism]{.smallcaps}*[^a^](#TF1){ref-type="table-fn"}*               Single cell org.~[caro]{.smallcaps}~, multi-cellular org.~[caro]{.smallcaps}~                            *Human, mice, C. albicans*                            722
  A[natomy]{.smallcaps}                                                                                                                                                                                                                     
      O[rganism subdivision]{.smallcaps}                                     Organism subdivision ~[caro]{.smallcaps}~                                                                *Head, thorax, hindlimb, legs*                        49
      A[natomical system]{.smallcaps}                                        Anatomical system~[caro]{.smallcaps}~                                                                    *Central nervous system, pulmonary system*            18
      O[rgan]{.smallcaps}                                                    Compound organ~[caro]{.smallcaps}~                                                                       *Heart, eyes, skin*                                   176
      M[ulti-tissue structure]{.smallcaps}                                   Multi-tissue structure~[caro]{.smallcaps}~                                                               *Blood vessel, peritoneal membrane, lymph nodes*      514
      T[issue]{.smallcaps}                                                   Portion of tissue~[caro]{.smallcaps}~                                                                    *Endothelium, adipose tissue, capillary*              426
      C[ell]{.smallcaps}                                                     Cell~[cl]{.smallcaps}~                                                                                   *Endothelial cells, HUVECs, pericyte, cancer cells*   1198
      C[ellular component]{.smallcaps}                                       Cellular component~[go]{.smallcaps}~                                                                     *Nuclei, focal adhesions, extracellular matrix*       145
      D[eveloping anatomical structure]{.smallcaps}                          Developing anatomical structure~[ehdaa]{.smallcaps}~                                                     *Embryo*                                              6
      O[rganism substance]{.smallcaps}                                       Portion of organism substance~[caro]{.smallcaps}~                                                        *Blood, serum, plasma, urine*                         142
      I[mmaterial anatomical entity]{.smallcaps}                             Immaterial anatomical entity~[caro]{.smallcaps}~                                                         *Lumen, preperitoneal space, marrow cavity*           15
      P[athological formation]{.smallcaps}                                   Cancer~[doid]{.smallcaps}~, benign neoplasm~[doid]{.smallcaps}~                                          *Tumor, colorectal cancer, gliomas*                   910
  M[olecule]{.smallcaps}                                                                                                                                                                                                                    
      D[rug or compound]{.smallcaps}*[^a^](#TF1){ref-type="table-fn"}*       Inorganic molecular entity~[c]{.smallcaps}h[ebi]{.smallcaps}~, drug~[c]{.smallcaps}h[ebi]{.smallcaps}~   *Oxygen, ethanol, bevacizumab, thalidomide*           944
      G[ene or gene product]{.smallcaps}*[^a^](#TF1){ref-type="table-fn"}*   Gene~[so]{.smallcaps}~, RNA~[chebi]{.smallcaps}~, protein~[chebi]{.smallcaps}~                           *VEGF, p53, IL-8, endostatin, thrombin*               2962

Labels in gray identify informal categories used in evaluation.

*^a^* Annotated also in previously introduced event extraction resources. t~o~ identifies a term t in an ontology o; ontology identifiers are OBO Foundry prefixes (namespaces).

For event types, we draw primarily on the biological process subontology of the gene ontology (GO) ([@B2]). As in previous event-annotated resources, we consider only general upper-level GO terms such as growth~GO~: references to specific processes included in GO through composite terms such as regulation of heart growth~GO~ are captured using the explicitly structured representation[^7^](#FN7){ref-type="fn"} ([Fig. 3](#F3){ref-type="fig"}). We also capture general statements of causal association using Regulation types, as in previous event annotation efforts (see e.g. [@B13]). Following the scope of the reference annotation, we introduce event annotation also for intentionally planned processes (e.g. injection) as outlined in the Ontology for Biomedical Investigations (OBI) ([@B7]), using a single, non-specific type Planned process for their annotation. We additionally introduce a Breakdown event for annotating pathological processes that result in the breakdown of anatomical structures. Finally, we apply the domain-specific Blood vessel development type to annotate references to blood vessel development through expressions such as 'angiogenesis' that incorporate both the process and the affected entity. Expressions such as 'blood vessel development' that allow explicitly structured annotation are marked with a separate entity annotation (e.g. 'blood vessel') and an event (e.g. 'development') taking the entity as its Theme. The primary event types are summarized in [Table 2](#T2){ref-type="table"}. Fig. 3.Annotation with detailed GO terms (top; hypothetical) and event annotation with general types (bottom; applied)

###### 

Primary event types, argument roles, related ontology terms and annotation counts

  Type                                                                                    Arguments                 Term(s)                                                            Examples                                               Count
  --------------------------------------------------------------------------------------- ------------------------- ------------------------------------------------------------------ ------------------------------------------------------ -------
  A[natomical]{.smallcaps}                                                                                                                                                                                                                    
      C[ell proliferation]{.smallcaps}                                                    *Theme*                   Cell proliferation~[go]{.smallcaps}~                               *proliferating \[ECs\], \[MCs\] accumulated*           133
      D[evelopment]{.smallcaps}                                                           *Theme*                   Developmental process~[go]{.smallcaps}~                            *\[skin\] development, \[stress fiber\] formation*     316
       B[lood vessel development]{.smallcaps}                                             *Theme, At-Loc*           Blood vessel development~[go]{.smallcaps}~                         *angiogenesis, neovascularization*                     855
      G[rowth]{.smallcaps}                                                                *Theme*                   Growth~[go]{.smallcaps}~                                           *growth \[of arteries\], \[tumour\] growth*            169
      D[eath]{.smallcaps}                                                                 *Theme*                   Death~[go]{.smallcaps}~                                            *\[connective tissue\] necrosis, \[cell\] apoptosis*   97
      B[reakdown]{.smallcaps}                                                             *Theme*                   ---                                                                *\[ECM\] degradation, damage \[to tumor cell\]*        69
      R[emodeling]{.smallcaps}                                                            *Theme*                   Tissue remodeling~[go]{.smallcaps}~                                *\[vascular\] remodeling, changes \[in membrane\]*     33
  M[olecular]{.smallcaps}                                                                                                                                                                                                                     
      S[ynthesis]{.smallcaps}                                                             *Theme*                   Biosynthetic process~[go]{.smallcaps}~                             *\[ATP\] synthesis, production \[of NOS\]*             17
      G[ene expression]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                     *Theme*                   Gene expression~[go]{.smallcaps}~                                  *expression \[of VEGF\]*                               435
      T[ranscription]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                       *Theme*                   Transcription, DNA-dependent~[go]{.smallcaps}~                     *\[VEGF\] mRNA expression*                             37
      C[atabolism]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                          *Theme*                   Catabolic process~[go]{.smallcaps}~                                *\[p53\] breakdown*                                    26
      P[hosphorylation]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                     *Theme, Site*             Phosphorylation~[go]{.smallcaps}~                                  *phosphorylation \[of KDR\]*                           33
      D[ephosphorylation]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                   *Theme, Site*             Dephosphorylation~[go]{.smallcaps}~                                *\[Mcl-1\] dephosphorylation*                          6
  G[eneral]{.smallcaps}                                                                                                                                                                                                                       
      L[ocalization]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                        *Theme, At/From/To-Loc*   Localization~[go]{.smallcaps}~                                     *\[VEGF\] colocalized, \[VPF was\] secreted*           450
      B[inding]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                             *Theme, Site*             Binding~[go]{.smallcaps}~, biological adhesion~[go]{.smallcaps}~   *\[cell\] adhesion, \[GDP-\]bound \[Rab5a\]*           184
      R[egulation]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                          *Theme, Cause, Site*      Biological regulation~[go]{.smallcaps}~                            *\[aMSH\] modulates \[activation of AP-1\]*            773
      P[ositive]{.smallcaps} [regulation]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*   *Theme, Cause, Site*      Pos.regulation of biol.proc. ~[go]{.smallcaps}~                    *\[insulin\] stimulates \[VEGF expression\]*           1327
      N[egative regulation]{.smallcaps}*[^a^](#TF2){ref-type="table-fn"}*                 *Theme, Cause, Site*      Neg.regulation of biol.proc. ~[go]{.smallcaps}~                    *Inhibition \[of NO synthase by L-NAME\]*              921
  P[lanned]{.smallcaps}                                                                                                                                                                                                                       
      P[lanned process]{.smallcaps}                                                       *Theme, Instrument*       Planned process~[obi]{.smallcaps}~                                 *injection \[of U-995\], \[UFT\] administration*       643

Labels in gray identify categories used in evaluation: events of the Anatomical category involve Organism or Anatomy entities ([Table 1](#T1){ref-type="table"}); Molecular involve Molecule entities; others can involve any entity type.

*^a^*Annotated also in previously introduced event extraction resources.

For event participants, we apply otherwise standard roles included also in previous efforts (e.g. Theme and Cause) but introduce the role Instrument for distinguishing entities used to carry out planned processes from those that undergo the effects of the process.[^8^](#FN8){ref-type="fn"} Also as in previously introduced event corpora, we apply two binary modifiers, Negation and Speculation, marking events as explicitly negated (e.g. 'cells did not proliferate') or stated in a speculative context (e.g. 'growth might be inhibited'), respectively.

We refer to the detailed annotation guidelines ([@B29]) for specifics of the annotation, but note here one systematic difference between our annotation and the scope of the reference ontologies: the ontologies define idealized types---canonical anatomy and physiological processes---but texts primarily refer to real-world instances that do not fill these exacting criteria ([@B3]). We thus interpreted the scope of mentions marked with a specific type to include not only the corresponding (canonical) types defined in ontologies but also variants such as entities or processes influenced by mutation, including also pathological variants. As specific examples, we mark '*cancer cell* as C[ell]{.smallcaps}', and '*\[cancer\] growth*' as Growth.

2.5 Annotation process {#SEC2.5}
----------------------

Primary annotation was performed by a PhD biologist with more than a decade of experience in text annotation who had previously coordinated several event annotation efforts (TO). Annotations were made using the brat rapid annotation tool ([@B38]).

Detailed annotation guidelines were prepared based on those for the GENIA and BioNLP Shared Task guidelines and refined throughout annotation to clarify ambiguous cases and document specific decisions made in annotation. We refer to the supplementary documentation and these guidelines ([@B29]) for further details of the annotation scheme and the detailed definitions of all annotated types.

3 METHODS {#SEC3}
=========

This section presents the automatic entity mention detection and event extraction methods applied in this study, their adaptation to the novel extraction targets and the experimental setup.

Following standard practice in domain event extraction studies, we divide the automatic extraction task into two separate stages, the detection of entity mentions and the extraction of events involving these and evaluate system performance on these two separately.

3.1 Entity mention detection {#SEC3.1}
----------------------------

For entity mention detection experiments, we applied NERsuite, a named entity recognition toolkit based on the CRFsuite implementation ([@B27]) of conditional random fields ([@B19]). NERsuite is capable of efficiently incorporating features based on token matching against large-scale lexical resources, and the applied version achieves an *F* score of 86.4% on the BioCreative II evaluation standard (GENETAG) ([@B39]), effectively matching the performance of the best available systems for the task.[^9^](#FN9){ref-type="fn"}

Following initial sentence splitting and tokenization, we perform lemmatization, POS-tagging and shallow parsing using the GENIA tagger ([@B40]). Next, we optionally perform a matching step using dictionaries compiled from the UMLS Metathesaurus ([@B5]), Entrez Gene ([@B20]) and OBO Foundry ([@B37]) resources. We then extract a comprehensive set of features for machine learning, building on orthographic, lexical, syntactic and dictionary match information (see [Supplementary information](http://bioinformatics.oxfordjournals.org/cgi/content/full/bts407/DC1)).

Following preliminary development test experiments, we chose to apply a single model that jointly predicts all entity types. In the final experiments, we compare a *base* model using only from the newly annotated data without external resources with a *dictionary*-supported model that incorporates features from matching against the lexical resources derived from UMLS, Entrez Gene and OBO foundry ontologies.

3.2 Event extraction {#SEC3.2}
--------------------

For event extraction, we applied EventMine,[^10^](#FN10){ref-type="fn"} a pipeline-based event extraction system using support vector machines (SVM). EventMine takes as input document text and entity annotations, and extracts event structures and modifications. EventMine outperforms the best systems participating in the original BioNLP Shared Task 2011 on the GE and ID data sets (with *F* scores 58.0% and 57.6%, respectively) and is competitive with the best systems on the EPI data set ([@B15]; [@B21]).

EventMine consists of four modules: (i) event trigger detection marks likely triggers and assigns them types, (ii) argument detection identifies likely trigger-argument pairs and assigns them roles, (iii) multi-argument event detection combines trigger-argument pairs into likely event structures and (iv) modification detection assigns modification flags (*Negation* and *Speculation*). Each module addresses its task as a multi-label classification problem, using the one-versus-rest SVM implementation of ([@B9]), with a rich feature set generated from tokens and paths in the predicate-argument structure analyses of the Enju parser ([@B22]) and the dependency analyses of the GDep parser ([@B34]). In feature generation, EventMine applies semantic class generalization---e.g. merging P[ositive regulation]{.smallcaps} and R[egulation]{.smallcaps} types for some features---to reduce the data sparsity and the number of different classes in the classification problems. In addition to training EventMine on the newly introduced corpus, we also introduced a set of generalization rules appropriate to the introduced types. We refer to supplementary documentation and ([@B21]) for further details on EventMine.

We performed event extraction experiments in two settings: training only on the newly introduced data (*base* model) and training using *stacking*, incorporating predictions from a model trained on the BioNLP Shared Task 2011 GE data set ([@B15]) as the source corpus. No other external resources were used in the evaluation.

3.3 Experimental setup {#SEC3.3}
----------------------

The annotated data were initially divided into training, development and test sets. The test set was held out during method development and parameter selection. For the final experiment, methods were trained on the combination of training and development data and evaluated on the test set.

We evaluate both entity mention detection and event extraction performance using the standard precision, recall and *F* score[^11^](#FN11){ref-type="fn"} metrics, microaveraged over instance-level true-positive, false-positive and false-negative counts.

For entity mention detection, we apply the evaluation protocol and tools of the BioNLP/JNLPBA shared task 2004 ([@B12]), evaluating results using three matching criteria: exact span match, left boundary match and right boundary match. The first requires the extent of a predicted entity mention to be identical to that of a gold mention for the prediction to be considered correct, whereas the latter two only require one of the boundaries defining the extent to match. We require the type of the predicted and annotated entities to be identical in all cases.

For event extraction, we adapt the evaluation protocol and tools introduced in the BioNLP Shared Task 2011 ([@B14]), including providing gold entity annotations as given for event extraction. We apply the primary matching criteria defined in the task, which otherwise require event structures to be identical but include the *approximate span* and *approximate recursive* relaxations to exact match: the former allows small variation in predicted event trigger spans and the latter permits differences in the secondary arguments of recursive event structures for matches. For detailed definitions, we refer to ([@B14]).

4 RESULTS AND DISCUSSION {#SEC4}
========================

We next present the primary results of the annotation effort and the entity mention detection and event extraction experiments.

4.1 Annotation effort and results {#SEC4.1}
---------------------------------

We estimate the concentrated effort to produce the corpus annotation to have totalled approximately 250 hours, of which approximately 100 hours used on guideline development, management and annotation consistency checking. The effort required to produce structured event annotation is thus broadly comparable to the initial effort by domain experts to mark text spans of interest ([@B41]).

[Table 3](#T3){ref-type="table"} presents the overall statistics of the annotated multilevel event extraction (MLEE) corpus. We note that the texts include comparable numbers of molecular and anatomy-level entity mentions, with a lower but still notable number of organism mentions. The event counts show a higher density of anatomical than molecular-level events, although general biological events dominate overall. Overall, 1222 events, or 18% of the total, involve either directly or indirectly (through participating events) arguments at both the molecular and anatomy levels ([Fig. 4](#F4){ref-type="fig"}). [Table 4](#T4){ref-type="table"} presents corpus statistics with reference to those for the three largest event-annotated corpora in the recent BioNLP shared task 2011. We note that although the MLEE corpus is smaller than these corpora focusing on the molecular level in terms of e.g. word count, there is less difference in the number of entity annotations, and the MLEE corpus has more event annotations than two of the shared task corpora. The introduced corpus thus has a very high density of event annotations, which we attribute in part to the novel entity and event types allowing a more comprehensive representation of statements in text. Fig. 4.Example Negative regulation (-Reg) event connecting entities at different levels of biological organization

###### 

Overall corpus statistics

  Item                           Train    Devel   Test     Total
  ------------------------------ -------- ------- -------- --------
  Document                       131      44      87       262
  Sentence                       1271     457     880      2608
  Word                           27 875   9610    19 103   56 588
  Entity                         4147     1431    2713     8291
      O[rganism]{.smallcaps}     359      126     237      722
      A[natomy]{.smallcaps}      1844     589     1166     3599
      M[olecule]{.smallcaps}     1944     716     1310     3970
  Event                          3296     1175    2206     6677
      A[natomical]{.smallcaps}   810      269     596      1675
      M[olecular]{.smallcaps}    340      125     240      705
      G[eneral]{.smallcaps}      1851     627     1176     3654
      P[lanned]{.smallcaps}      295      154     194      643

See [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} for entity and event categories.

###### 

Comparison of corpus statistics with BioNLP Shared Task 2011 corpora annotated using the same representation

  Item       MLEE     EPI       GE        ID
  ---------- -------- --------- --------- --------------------------------------
  Document   262      1200      1224      30*[^a^](#TF3){ref-type="table-fn"}*
  Word       56 588   253 628   348 908   153 153
  Entity     8291     15190     21616     12740
  Event      6677     3714      24967     4150

*^a^* The ID document count is low as the corpus consists of full-text documents, not abstracts.

We refer to [Supplementary Material Section 1.3](http://bioinformatics.oxfordjournals.org/cgi/content/full/bts407/DC1) for an evaluation of the corpus annotation consistency.

4.2 Entity mention detection {#SEC4.2}
----------------------------

The overall evaluation results for entity mention detection are listed in [Table 5](#T5){ref-type="table"}. We find a consistent benefit from the use of the lexical resources, with e.g. a 3.6% point improvement in *F* score (15% reduction in error) for strict matching. As expected, evaluated performance is notably higher under the relaxed criteria, in particular for right boundary matching. This suggests comparatively many errors in the choice of noun premodifiers included in annotation span, a distinction that may not be of critical importance for many applications.

###### 

Overall entity mention detection results (prec/rec/*F* score)

  Model        Exact                   Matching criterion      
  ------------ ----------------------- ----------------------- -----------------------
  Base         77.03 / 69.18 / 72.89   79.85 / 71.72 / 75.57   82.47 / 74.07 / 78.04
  Dictionary   79.49 / 73.77 / 76.52   82.59 / 76.64 / 79.50   84.68 / 78.58 / 81.52

[Table 6](#T6){ref-type="table"} lists a breakdown of performance by entity category for the dictionary model. The detection of Organism mentions is most reliable despite their sparseness in the data, conforming to previous results indicating this entity class to represent a comparatively easy problem ([@B10]). The detection of mentions of entities of the A[natomy]{.smallcaps} and M[olecule]{.smallcaps} categories can be performed at broadly comparable accuracy on this corpus containing balanced numbers of annotations of the two, suggesting that fine-grained anatomical entity detection is no more difficult than established molecular level entity detection tasks.

###### 

Entity mention detection results by category for dictionary model (prec/rec/*F* score)

  Category                 Exact                   Matching criterion      
  ------------------------ ----------------------- ----------------------- -----------------------
  O[rganism]{.smallcaps}   90.82 / 82.10 / 86.24   91.79 / 82.97 / 87.16   91.79 / 82.97 / 87.16
  A[natomy]{.smallcaps}    77.47 / 72.70 / 75.01   78.67 / 73.83 / 76.17   84.58 / 79.38 / 81.90
  M[olecule]{.smallcaps}   79.37 / 73.25 / 76.18   84.54 / 78.03 / 81.15   83.54 / 77.10 / 80.19

The overall entity mention detection performance, approaching or exceeding 80% in *F* score depending on evaluation criteria, is a very promising result given the novelty of the task and its many challenging aspects, most obviously that it involves more than 10 distinct entity types. As points of comparison, the best single system at the well-established single-class BioCreative 2 Gene Mention task achieved an *F* score of 87.2% under matching criteria that in cases accept more than one specific span as correct ([@B42]) and the highest-performing system at the original BioNLP/JNLPBA shared task, involving the detection of entities of five different types, achieved an *F* score of 72.6% under the exact matching criterion ([@B12]).

4.3 Event extraction {#SEC4.3}
--------------------

The overall results for event extraction using EventMine are presented in [Table 7](#T7){ref-type="table"}. The results demonstrate that the stacked model incorporating information from the previously introduced GE corpus outperforms a purely corpus-internal model. Although the improvement from incorporating the independently annotated out-of-domain data is somewhat modest, the result does indicate that the annotation has met its aim to maintain compatibility with this key resource for molecular-level event annotation.

###### 

Overall event extraction results

  Model           Prec    Rec     *F* score
  --------------- ------- ------- -----------
  Base            56.53   48.72   52.34
  Stacking (GE)   56.38   50.77   53.43

As for entity mention detection, performance for the best model, at over 50% *F* score for event extraction, is very promising for a first experiment on the new task. For reference, the best results in the recent, widely attended BioNLP Shared Task 2011 for the same evaluation criteria were 56.0% *F* score for the GE task, 53.3% *F* score for the EPI task and 55.6% *F* score for the ID task ([Table 4](#T4){ref-type="table"}) ([@B15]). Reaching this general level of performance suggests that the task is feasible for current event extraction technology and that the annotation consistency and the size of the introduced corpus are sufficient for reliable extraction.

[Table 8](#T8){ref-type="table"} gives a breakdown of the event extraction performance by category. Interestingly, we find that events involving anatomical entities are more reliably extracted than those involving molecular-level ones, despite the model incorporating information from a corpus with a larger number of molecular level event annotations than the total number of annotations in the MLEE corpus. This is a very encouraging finding for event extraction for anatomical processes, indicating that the representation and extraction methods are well suited for the task.

###### 

Event extraction results by category for stacked model

  Category                     Prec    Rec     *F* score
  ---------------------------- ------- ------- -----------
  A[natomical]{.smallcaps}     80.91   72.05   76.22
  M[olecular]{.smallcaps}      68.44   75.63   71.86
  G[eneral]{.smallcaps}        43.87   38.99   41.29
  P[lanned]{.smallcaps}        56.68   51.96   54.22
  M[odification]{.smallcaps}   47.95   29.92   36.85

Event categories as defined in [Table 2](#T2){ref-type="table"}; *Modification* gives performance for *Negation* and *Speculation* detection.

5 CONCLUSION {#SEC5}
============

We have presented the MLEE corpus, a resource aiming to extend the coverage of resources and methods for structured event extraction from the molecular level to encompass all levels from the subcellular to the organism. Experiments using state-of-the-art entity mention detection and event extraction methods demonstrated that the newly proposed extraction targets can be met with reasonable performance using the MLEE corpus, with approximately 80% overall *F* score for entity mention detection and over 50% *F* score for event extraction using standard evaluation criteria.

In future work, we will focus on the extension of the annotations and extraction methods to improve the domain independence of our annotation to allow the application of the introduced extraction methods at large scale to automatically annotate the entire available literature. The results of these extraction efforts will be made available through search systems such as MEDIE to further improve access to the biomedical literature by facilitating structured semantic queries across multiple levels of biological organization, for example to find statements regarding the inhibition of organ growth by specific molecular-level entities or events.

All resources introduced in this study, including the annotated corpus, guidelines, the evaluation tools and the methods are available from <http://nactem.ac.uk/MLEE/>.
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^1^<http://www.nactem.ac.uk/medie/>.

^2^Some recent tasks have considered also organisms (primarily unicellular, see e.g. [@B6]; [@B31]), but prior event extraction efforts have not specifically targeted entities and processes between the molecular and organism levels.

^3^We use the terms 'entity' and 'event' primarily following usage in IE, to identify forms of representation, not ontological categories. In particular, the latter term does not denote a category distinct from processes.

^4^<http://obofoundry.org>.

^5^Although the existing corpus annotation of ([@B41]) identifies such mentions, they are typed nonspecifically, using e.g. P[ositive regulation]{.smallcaps} to mark '*development*' and N[egative regulation]{.smallcaps} for '*\[cell\] death*'.

^6^Note that we differentiate between types applied in annotation and their (broadly) corresponding ontology types.

^7^This annotation strategy can be viewed as partly analogous to efforts to make GO term structure explicit ([@B23]).

^8^For example in '*rats were injected with hyperforin*', the O[rganism]{.smallcaps} mention ('*rats*') is the *Theme* of the P[lanned process]{.smallcaps} ('*injected*') and the D[rug or compound]{.smallcaps} mention ('*hyperforin*') is the *Instrument*.

^9^<http://nersuite.nlplab.org>

^10^<http://www.nactem.ac.uk/EventMine/>

^11^Specifically where *p* is precision and *r* recall.
